MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5000
+0.0030
+0.60%
After Hours: 0.5150 +0.015 +3.00% 17:19 02/21 EST
OPEN
0.4820
PREV CLOSE
0.4970
HIGH
0.5150
LOW
0.4820
VOLUME
479.75K
TURNOVER
--
52 WEEK HIGH
4.630
52 WEEK LOW
0.4640
MARKET CAP
10.34M
P/E (TTM)
-0.2102
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACHV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACHV stock price target is 11.00 with a high estimate of 20.00 and a low estimate of 2.000.

EPS

ACHV News

More
  • Achieve Life Sciences Announces Agreement With FreeMind Group To Assist In Securing Non-Dilutive Funding To Evaluate Cytisinicline In Vaping And e-Cigarette Users
  • Benzinga · 02/06 13:11
  • Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
  • PR Newswire · 02/06 13:00
  • Oracle cloud improves speed of drug discovery
  • Seeking Alpha - Article · 01/13 13:31
  • Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
  • PR Newswire · 01/13 11:30

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ACHV

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
More

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.